Teva Pharmaceutical Industries (TEVA) Income from Non-Controlling Interests (2009 - 2025)

Teva Pharmaceutical Industries (TEVA) has reported Income from Non-Controlling Interests for 17 consecutive years, with $1.0 million the latest figure, recorded in Q3 2025.

• Quarterly Income from Non-Controlling Interests fell 97.87% year-over-year to $1.0 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $7.0 million (up 102.19% YoY) and the FY2025 annual result came in at $7.0 million, up 102.19% from the prior year.
• Income from Non-Controlling Interests declined to $1.0 million in Q3 2025 per TEVA's latest filing, from $6.0 million in the prior quarter.
• Over the last five years, Income from Non-Controlling Interests for TEVA reached as high as $47.0 million in Q3 2024 and fell as low as -$280.0 million in Q1 2024.
• A 5-year average of -$21.3 million and a median of $3.0 million in 2022 frame the typical range for Income from Non-Controlling Interests.
• The largest YoY upside for Income from Non-Controlling Interests was 487.5% in 2024 against a maximum downside of 1550.0% in 2024.
• Year by year, Income from Non-Controlling Interests stood at $7.0 million in 2021, then sank by 557.14% to -$32.0 million in 2022, then soared by 112.5% to $4.0 million in 2023, then tumbled by 1550.0% to -$58.0 million in 2024, then soared by 101.72% to $1.0 million in 2025.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $1.0 million, $6.0 million, and -$58.0 million for Q3 2025, Q1 2025, and Q4 2024 respectively.